Open AccessSelection of a Surrogate Agent (Vancomycin or Teicoplanin) for Initial Susceptibility Testing of Dalbavancin: Results from an International Antimicrobial Surveillance Program
Author(s) -
Ronald N. Jones,
Hélio S. Sader,
Thomas R. Fritsche,
Patricia A. Hogan,
Daniel J. Sheehan
Publication year - 2006
Publication title -
journal of clinical microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.349
H-Index - 255
eISSN - 1070-633X
pISSN - 0095-1137
DOI - 10.1128/jcm.00576-06
Subject(s) - dalbavancin , teicoplanin , vancomycin , glycopeptide , medicine , antimicrobial , microbiology and biotechnology , antibiotics , biology , staphylococcus aureus , bacteria , genetics
The immediate lack of market-dominating commercial products (Vitek or MicroScan) for susceptibility testing of the new glycolipopeptide, dalbavancin, requires a surrogate marker agent to assist microbiologists in the correct categorization of potentially indicated species (staphylococci and streptococci). Error-rate analyses for 16,749 isolates using vancomycin or teicoplanin results to categorize dalbavancin susceptibilities demonstrated that both glycopeptide agents were highly predictive of dalbavancin-susceptible results (nearly 100%) with only a rare minor error. Vancomycin test results most reliably predict dalbavancin susceptibility until validated commercial reagents become available for direct testing in clinical practice.